<DOC>
	<DOCNO>NCT01521702</DOCNO>
	<brief_summary>The aim study test additional value neoadjuvant chemotherapy standard treatment resectable pancreatic cancer ( surgery + adjuvant chemotherapy ) . This study perform compliance study protocol , GCP ( good clinical practice ) applicable regulatory requirement .</brief_summary>
	<brief_title>NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine Resectable PAncreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>resectable adenocarcinoma pancreatic head ( require duodenopancreatectomy ) T13 , Nx , M0 ( UICC 6th version , 2002 ) infiltration portal vein ( &lt; 180° ) exclusion criterion cytologic histologic confirmation adenocarcinoma age &gt; 18 year write informed consent contraindication Whipple procedure infiltration &gt; 180° portal vein abutment tumor superior mesenteric artery infiltration superior mesenteric artery celiac trunk chronic neuropathy &gt; grade 2 WHO performance score &gt; 2 uncorrectable cholestasis ( bilirubin &gt; 100mmol/l despite drainage attempt four week prior inclusion ) female patient child bear age use adequate contraception ( oral subcutaneous contraceptive , intrauterine pessars ( IUP ) , condom ) pregnant lactate woman mental organic disorder could interfere give informed consent receive treatment Second malignancy diagnose within past 5 year , except nonmelanomatous skin cancer noninvasive cervical cancer percutaneous biopsy primary tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>pancreatic head</keyword>
</DOC>